You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

34 search results for: coexisting diseases

Shared and Unique Characteristics of AD, PN, and CSU
expert video

Shared and Unique Characteristics of AD, PN, and CSU

Dermatology
Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation
expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Dermatology
Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
Itch in AD, PN and CSU: Role of Type 2 Inflammation
expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

Dermatology
Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.
View more
The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

Dermatology
Explore how atopic dermatitis persists and advances, spanning childhood to adulthood via this informative infographic.
View more
Can advanced systemic therapies modify pathomechanisms in AD?
expert video

Can advanced systemic therapies modify pathomechanisms in AD?

Dermatology
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
View more
Can early intervention modify the course of AD?
expert video

Can early intervention modify the course of AD?

Dermatology
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
View more
The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers
expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

Dermatology
Discover the multidimensional impact of pediatric atopic dermatitis on children and caregivers – a soundbite from the Expert Lounge Canada 2022.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region